ROR1 and sarcoma: Additional novel targets include the type 1 insulin-like growth factor receptor (IGF1R) and receptor tyrosine kinase-like orphan receptor 1 (ROR1) for sarcoma as well as the L1-cell adhesion molecule (L1-CAM) for ovarian cancer [51].